Matches in SemOpenAlex for { <https://semopenalex.org/work/W2068077021> ?p ?o ?g. }
Showing items 1 to 92 of
92
with 100 items per page.
- W2068077021 endingPage "662" @default.
- W2068077021 startingPage "655" @default.
- W2068077021 abstract "The efficacy and safety of docetaxel-epirubicin chemotherapy in the treatment of metastatic breast cancer was investigated in Chinese women. Three-weekly cycles comprised epirubicin 75 mg/m2 i.v. followed 1 h later by docetaxel 75 mg/m2 i.v. After 3 cycles, responding patients received a further 3 cycles, followed by 3 cycles of docetaxel alone. Forty-six patients entered the study, of whom 37% had received prior adjuvant chemotherapy. Three patients withdrew due to toxicity and were not evaluable for response. There were five complete responses and 31 partial responses, giving an overall response rate of 83.7% (95% CI 72.7-94.8%). The median time to progression was 10.96 months (95% CI 7.76-12.86) and median survival was 24.2 months (95% CI 16.6-). The most common grade 3/4 adverse events were neutropenia (96% of patients) and neutropenia with fever (39%). Hepatotoxicity occurred in six patients, two being attributable to hepatitis B virus reactivation. No patients suffered grade 3/4 cardiac toxicity and there were no treatment-related mortalities. Quality of life aspects deteriorated after 3 cycles, but there was a trend towards improved emotional aspects after 9 cycles. We conclude that docetaxel-epirubicin chemotherapy is highly effective for recurrent metastatic/locoregional breast cancer, with myelosuppression being the main toxicity." @default.
- W2068077021 created "2016-06-24" @default.
- W2068077021 creator A5006449106 @default.
- W2068077021 creator A5007089296 @default.
- W2068077021 creator A5017408978 @default.
- W2068077021 creator A5017578791 @default.
- W2068077021 creator A5025112401 @default.
- W2068077021 creator A5030276921 @default.
- W2068077021 creator A5042632184 @default.
- W2068077021 creator A5046604568 @default.
- W2068077021 creator A5052600455 @default.
- W2068077021 creator A5066717752 @default.
- W2068077021 creator A5088851557 @default.
- W2068077021 date "2002-07-01" @default.
- W2068077021 modified "2023-10-18" @default.
- W2068077021 title "Phase II study of docetaxel and epirubicin in Chinese patients with metastatic breast cancer" @default.
- W2068077021 cites W1837236202 @default.
- W2068077021 cites W1960713055 @default.
- W2068077021 cites W1967577450 @default.
- W2068077021 cites W1974513579 @default.
- W2068077021 cites W1990401132 @default.
- W2068077021 cites W2025111649 @default.
- W2068077021 cites W2040719842 @default.
- W2068077021 cites W2048564699 @default.
- W2068077021 cites W2057129759 @default.
- W2068077021 cites W2073533584 @default.
- W2068077021 cites W2077187782 @default.
- W2068077021 cites W2086897201 @default.
- W2068077021 cites W2155199802 @default.
- W2068077021 cites W2156641782 @default.
- W2068077021 cites W2167244629 @default.
- W2068077021 cites W2171701166 @default.
- W2068077021 cites W2183288147 @default.
- W2068077021 cites W2188493006 @default.
- W2068077021 cites W2203687533 @default.
- W2068077021 cites W2242824667 @default.
- W2068077021 cites W2244010327 @default.
- W2068077021 cites W2321548334 @default.
- W2068077021 cites W2740368365 @default.
- W2068077021 doi "https://doi.org/10.1097/00001813-200207000-00013" @default.
- W2068077021 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12172512" @default.
- W2068077021 hasPublicationYear "2002" @default.
- W2068077021 type Work @default.
- W2068077021 sameAs 2068077021 @default.
- W2068077021 citedByCount "11" @default.
- W2068077021 countsByYear W20680770212012 @default.
- W2068077021 countsByYear W20680770212013 @default.
- W2068077021 countsByYear W20680770212015 @default.
- W2068077021 countsByYear W20680770212016 @default.
- W2068077021 countsByYear W20680770212021 @default.
- W2068077021 crossrefType "journal-article" @default.
- W2068077021 hasAuthorship W2068077021A5006449106 @default.
- W2068077021 hasAuthorship W2068077021A5007089296 @default.
- W2068077021 hasAuthorship W2068077021A5017408978 @default.
- W2068077021 hasAuthorship W2068077021A5017578791 @default.
- W2068077021 hasAuthorship W2068077021A5025112401 @default.
- W2068077021 hasAuthorship W2068077021A5030276921 @default.
- W2068077021 hasAuthorship W2068077021A5042632184 @default.
- W2068077021 hasAuthorship W2068077021A5046604568 @default.
- W2068077021 hasAuthorship W2068077021A5052600455 @default.
- W2068077021 hasAuthorship W2068077021A5066717752 @default.
- W2068077021 hasAuthorship W2068077021A5088851557 @default.
- W2068077021 hasConcept C121608353 @default.
- W2068077021 hasConcept C126322002 @default.
- W2068077021 hasConcept C143998085 @default.
- W2068077021 hasConcept C2775930923 @default.
- W2068077021 hasConcept C2776694085 @default.
- W2068077021 hasConcept C2780835546 @default.
- W2068077021 hasConcept C2781190966 @default.
- W2068077021 hasConcept C530470458 @default.
- W2068077021 hasConcept C71924100 @default.
- W2068077021 hasConceptScore W2068077021C121608353 @default.
- W2068077021 hasConceptScore W2068077021C126322002 @default.
- W2068077021 hasConceptScore W2068077021C143998085 @default.
- W2068077021 hasConceptScore W2068077021C2775930923 @default.
- W2068077021 hasConceptScore W2068077021C2776694085 @default.
- W2068077021 hasConceptScore W2068077021C2780835546 @default.
- W2068077021 hasConceptScore W2068077021C2781190966 @default.
- W2068077021 hasConceptScore W2068077021C530470458 @default.
- W2068077021 hasConceptScore W2068077021C71924100 @default.
- W2068077021 hasIssue "6" @default.
- W2068077021 hasLocation W20680770211 @default.
- W2068077021 hasLocation W20680770212 @default.
- W2068077021 hasOpenAccess W2068077021 @default.
- W2068077021 hasPrimaryLocation W20680770211 @default.
- W2068077021 hasVolume "13" @default.
- W2068077021 isParatext "false" @default.
- W2068077021 isRetracted "false" @default.
- W2068077021 magId "2068077021" @default.
- W2068077021 workType "article" @default.